13 results about "Viral entry" patented technology

This invention relates to an anti-swine pseudorabies virus (PRV) preparation and the application of Rehmannia glutinosa polysaccharide in its preparation, belonging to the field of biopharmaceutical technology. This invention provides an anti-swine pseudorabies virus (PRV) preparation comprising Rehmannia glutinosa polysaccharide. It also provides the application of Rehmannia glutinosa polysaccharide in the preparation of an anti-PRV preparation for the prevention and / or treatment of swine pseudorabies. This invention utilizes Rehmannia glutinosa polysaccharide to prevent infection by the PRV variant XJ5 by reducing intracellular oxidative stress levels; it also resists viral infection by affecting viral adsorption. Furthermore, when the concentration of Rehmannia glutinosa polysaccharide is between 50 and 400 μg / mL, it can also affect viral entry and replication, and has no cytotoxicity to PK-15 cells.

The present invention provides a mammalian cell line that has been genetically engineered to make it resistant to viral entry and / or replication; and provides a method for using the cell line to reduce or prevent viral contamination of a bioproduction system.

The application relates to the field of biological medicine, and particularly relates to application of Navitoclax (ABT263) in preparation of a broad-spectrum antiviral inhibitor. The application of the compound Navitoclax (ABT263), an analogue or a salt thereof shown in formula (I) in preparation of a broad-spectrum antiviral inhibitor. It is found in the application that the compound has broad-spectrum antiviral activity, including but not limited to SARS-CoV-2, SARS-CoV, MERS-CoV, the compound can act on the virus entry stage, and the virus is resisted outside the target cell. In addition, the compound has a high selection index (CC50 / IC50) for different viruses, and has considerable safety. The application provides a broad-spectrum antiviral small-molecule compound, which has the advantages of simple preparation method, low cost, easy transportation and storage, high safety and good activity, and has a broad prospect in the fields of biological medicine and response to new emerging infectious diseases.

The present invention relates to the treatment of inflammatory diseases. Here, the inventors analyzed the immune activation triggered by HRV16 in macrophages to elucidate the cellular pathways involved in ARL5b upregulation. They demonstrated that HRV16 does not replicate in macrophages but induces interferon and pro-inflammatory responses. Conversely, in HeLa OHIO cells where the virus replicates, no induction of immune responses is observed. They identify the ICAM1-PKR-ATF2 axis as the primary regulator of HRV16-mediated ARL5b induction in macrophages. By contrast, HRV16-mediated ARL5b decrease in HeLa OHIO is dependent on ICAM-1 / viral entry in the cells but not on PKR signalling. Finally, ARL5b is regulated at the epigenetic level in both HeLa OHIO and human macrophages. An increase in the repressive mark H3K27Me3 is observed in HeLa OHIO, while the activating mark H3K27Ac is increased on the ARL5b promoter in human macrophages. Thus, the invention relates to relates to an inhibitor of the ICAM1 / PKR / ATF2 signalling pathway for use in the improvement of phagocytosis in a subject in need thereof.

The invention relates to anti-viral compounds suitable for use in blocking virus entry into cells, and methods of blocking virus entry into cells by associating the cells with the anti-viral compounds. The associating may occur in vitro, or in vivo in a subject through administration of the anti-viral compounds to the subject. The invention also relates to methods of treating or preventing a viral infection in a subject by administering to the subject at least one anti-viral compound. The subject may be a human being suffering from or vulnerable to the viral infection. The virus may include a coronavirus, such as severe acute respiratory syndrome-related coronavirus 2 (SARS-COV-2).

The invention relates to the technical field of gene engineering, in particular to an avian infectious bronchitis virus system based on double reporter genes and application thereof. According to the avian infectious bronchitis virus system based on the double reporter genes, real-time monitoring of IBV infection and replication can be achieved, the detection sensitivity and specificity are improved, meanwhile, experimental operation is simplified, and cost is reduced. The system can be used for various applications including but not limited to virus susceptible cell testing, virus entry mechanism research, antiviral drug screening, vaccine and neutralizing antibody effect evaluation, virus intrusion inhibitor evaluation and influence research of virus variation on infectivity. The system and the method provided by the invention provide a new tool for research and prevention and control of IBV and other enveloped viruses, and have important scientific and practical application values.

This invention discloses a method for manufacturing a negative ion device for preventing and treating airborne viral infections. Specifically, water is added to tourmaline pebbles to moisten them, but not completely immerse them, and additional air pressure is applied to the surface of the wet tourmaline pebbles. The pressure of the tourmaline is used to generate a pressure-electric electrode that is far greater than the spontaneous polarization effect, ionizing surrounding water molecules to produce a large number of hydroxide and hydrogen ions. Hydrogen ions have a weaker electron-capturing ability compared to oxygen molecules and are the lightest substance, so they disperse immediately after being blown out by the fan, resulting in a very low content in the environment. After the hydroxide ions donate electrons, water and oxygen are produced, and the electrons that donate them combine with oxygen molecules blown in by the fan and oxygen molecules produced by their own reactions to form intrinsic negative ions by Brownian motion. Using these negative ions obtained through the Green method, it is possible to promote the decomposition of VOCs, condense and settle PM2.5, aerosols, bacteria, viruses, pollen, etc., inhibit or kill bacteria, change or reverse the polarity of the potential inside and outside the viral capsid, break down the viral spike, rapidly inactivate viruses, and prevent viruses from entering human cells by blocking electrostatic attraction between the viral receptor binding region and the cell membrane receptor. At the same time, it has other health and therapeutic effects such as alleviating respiratory allergies, improving respiratory and circulatory functions, aiding sleep, preventing fatigue, antioxidant, removing free radicals in the body, increasing the body's repair capacity, and enhancing immunity. It can also generate and replenish diffused oxygen and perform mist-free humidification.

The invention relates to an application of torreya grandis aril volatile oil in preparation of a medicine for resisting porcine epidemic diarrhea virus. The torreya grandis aril volatile oil is volatile oil extracted from torreya grandis' Merrillii 'Hu aril of a torreya plant of taxus chinensis family. Researches show that the torreya grandis aril volatile oil can effectively and directly kill viruses, prevent the viruses from entering cells, inhibit the viruses from being copied in the cells and play a role in resisting the porcine epidemic diarrhea viruses, and can be applied to preparation of the medicines for resisting the porcine epidemic diarrhea viruses. The torreya grandis aril volatile oil is rich and cheap in raw materials, simple in preparation process and low in cost, and has good development and application prospects.

The present invention relates to the treatment of inflammatory diseases. Here, the inventors analyzed the immune activation triggered by HRV16 in macrophages to elucidate the cellular pathways involved in ARL5b upregulation. They demonstrated that HRV16 does not replicate in macrophages but induces interferon and pro-inflammatory responses. Conversely, in HeLa OHIO cells where the virus replicates, no induction of immune responses is observed. They identify the ICAM1-PKR-ATF2 axis as the primary regulator of HRV16-mediated ARL5b induction in macrophages. By contrast, HRV16-mediated ARL5b decrease in HeLa OHIO is dependent on ICAM-1 / viral entry in the cells but not on PKR signalling. Finally, ARL5b is regulated at the epigenetic level in both HeLa OHIO and human macrophages. An increase in the repressive mark H3K27Me3 is observed in HeLa OHIO, while the activating mark H3K27Ac is increased on the ARL5b promoter in human macrophages. Thus, the invention relates to relates to an inhibitor of the ICAM1 / PKR / ATF2 signalling pathway for use in the improvement of phagocytosis in a subject in need thereof.

The invention discloses application of a radix tetrastigme extract in preparation of a medicine for resisting Crimean-Congo hemorrhagic fever virus, and belongs to the technical field of medicine. The anti-CCHFV effect of the radix tetrastigme extract is evaluated on the cellular level by utilizing a CCHFV virus-like particle system capable of simulating virus endocytosis and transcriptional activity, and the result shows that the radix tetrastigme extract has remarkable antiviral activity, is dose-dependent, and has a good application prospect. The antiviral activity mechanism of the radix tetrastigme extract is related to virus cell entry and virus transcription stages. The radix tetrastigme extract provided by the invention shows the activity of inhibiting the CCHFV, and has a wide prospect of being developed into a medicine for treating human CCHFV infection.

This invention discloses a chimeric antiviral cross-protective antigen mRNA vaccine, its preparation method, and its application. The vaccine consists of lipid materials encapsulating either a first or second type of mRNA, forming nanolipid nanoparticles containing mRNA fragments. The first type of mRNA is obtained through in vitro transcription using a first DNA template, and the second type of mRNA is obtained through in vitro transcription using a second DNA template. The vaccine of this invention possesses the advantage of multi-antigen comprehensive immunity: each vaccine combines one EEV core surface antigen and one IMV core surface antigen. This chimeric strategy can simultaneously induce highly efficient and specific immunity against both types of viral infection particles, both limiting initial viral entry into cells and effectively clearing free viruses from the circulatory system. It not only stimulates strong humoral immunity but also induces specific cellular immune responses, thereby significantly enhancing the vaccine's broad-spectrum cross-protective efficacy against orthopox, vaccinia virus, and other orthopox viruses.

The present application relates to viral entry inhibitors and RNA polymerase inhibitors, pharmaceutical compositions comprising one or more of the same, and combination therapies, as well as methods of making and of using the foregoing in the treatment of certain diseases.

A pharmaceutical composition with dual anti-inflammatory and antiviral activity against COVID-19 and related respiratory pathogens, the composition comprising the following: (a) Curcumin in an amount of 1.5 to 5.0% by weight, which acts as a primary anti-inflammatory agent, suppressing cyclooxygenase-2 (COX-2) expression and interleukin-6 (IL-6) signaling; b) Quercetin in an amount of 2.0 to 6.0 wt%, which acts as an antiviral flavonoid and is able to inhibit SARS-CoV-2 proteases (3CLpro and PLpro) and the penetration of the virus; (c) Zinc oxide nanoparticles (ZnO-NPs) in an amount of 0.5 to 2.0 wt%, with an average particle size between 20 and 40 nm, which facilitate the destruction of viral envelope proteins and increase cellular zinc uptake; d) Ascorbic acid (vitamin C) in an amount of 1.0 to 4.0 wt.%, which acts as an antioxidant to neutralize reactive oxygen species (ROS) produced during viral infections and inflammatory reactions; (e) Glycyrrhizin, extracted from licorice glabra, in an amount of 1.0 to 3.0% by weight, acts as an immunomodulator, stabilizes cytokine levels and reduces pneumonia; and (f) a pharmaceutically acceptable carrier medium consisting of liposomal, polymeric or PEG-based excipients in an amount of 80 to 90 wt.%, which ensures sustained release and improved bioavailability of the active substances.